NEUROTECH
Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases—including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.
NEUROTECH
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
1995-01-01
Address:
Lincoln, Rhode Island, United States
Country:
United States
Website Url:
http://www.neurotechpharmaceuticals.com
Total Employee:
11+
Status:
Active
Contact:
401-333-3880
Email Addresses:
[email protected]
Total Funding:
49.13 M USD
Technology used in webpage:
SPF Google Font API Google Maps Microsoft Azure DNS GStatic Google Static Content Google Maps API Network Solutions DNS IIS 7 GoDaddy CDN Mimecast
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Investors List
Burrill & Company
Burrill & Company investment in Series B - Neurotech
Triginta Capital
Triginta Capital investment in Series B - Neurotech
Mayflower
Mayflower investment in Series B - Neurotech
Pound Capital
Pound Capital investment in Series B - Neurotech
Omega Funds
Omega Funds investment in Series B - Neurotech
Excalibur Fund Managers
Excalibur Fund Managers investment in Series B - Neurotech
Atlas Venture
Atlas Venture investment in Series B - Neurotech
Nexus Medical Partners
Nexus Medical Partners investment in Series B - Neurotech
Apax Partners
Apax Partners investment in Series B - Neurotech
Versant Ventures
Versant Ventures investment in Series B - Neurotech
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-01 | Neurotech Pharmaceuticals Appoints Thomas Aaberg Jr., M.D. as Chief Medical Officer |
Official Site Inspections
http://www.neurotechpharmaceuticals.com
- Host name: 104.238.180.94.vultrusercontent.com
- IP address: 104.238.180.94
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Neurotech"
Neurotech Pharmaceuticals, Inc. - Encapsulated Cell Therapy
Jun 20, 2024 · Neurotech is a private clinical stage biotech company focused on developing transformative therapies for chronic eye disease. The core platform technology, Encapsulated …See details»
Macular Telangiectasia | About Neurotech …
At Neurotech, we are focused on developing transformative therapies for chronic retinal diseases. Our unique scientific approach and novel Encapsulated Cell Therapy Platform promotes therapeutic advancements to treat a broad array …See details»
Encapsulated Cell Therapy | Science & Technology | Neurotech
ECT is a unique and versatile platform with the ability to continuously produce and deliver targeted therapeutics both singly or in combination, to the back of the eye long-term. ECT …See details»
Neurotech Pharmaceuticals, Inc. | LinkedIn
Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing...See details»
FDA grants Priority Review to novel treatment for …
Jun 20, 2024 · Neurotech announced that the investigative implant revakinagene taroretcel (NT-501) has been approved for Priority Review of Biologics License Application (BLA) by the FDA and has been granted a prescription drug user …See details»
Neurotech Pharmaceuticals, Inc. - MassBio
Neurotech Pharmaceuticals is a biotechnology company developing sight saving therapies for retinal diseases. We are ophthalmic scientists, engineers, technologists, and clinicians – all …See details»
Neurotech Pharmaceuticals - VentureRadar
Website: https://www.neurotechpharmaceuticals.com Develops Encapsulated Cell Technology (ECT) for long-term, steady-state delivery of therapeutic protein drugs in ocular diseases, …See details»
Neurotech Pharmaceuticals - Overview, News & Similar
View Neurotech Pharmaceuticals (www.neurotechpharmaceuticals.com) location in Rhode Island, United States , revenue, industry and description. Find related and similar companies as well …See details»
Neurotech Pharmaceuticals, Inc. Receives Priority Review of …
CUMBERLAND, R.I., June 20, 2024 -- (BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, announces that the U.S. Food …See details»
Clinical Trial | Macular Telangiectasia - neurotech
Feb 8, 2023 · With our clinical trials, Neurotech Pharmaceuticals, Inc. has developed treatment for retinal degenerative diseases. Learn more!See details»
Neurotech Provides Update on BLA for NT-501 as a Treatment for …
CUMBERLAND, R.I., November 08, 2024--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and …See details»
Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation …
Feb 12, 2019 · Neurotech Pharmaceuticals, Inc. is a private biotechnology company focused on developing transformative therapies for chronic eye diseases. The core technology platform, …See details»
Neurotech Pharmaceuticals receives priority review of BLA for NT …
Jun 20, 2024 · Neurotech Pharmaceuticals Inc announced the FDA has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for …See details»
Careers | Neurotech Pharmaceuticals, Inc. | Cumberland, RI
Learn more about how you can be part of our team and delivering MacTel treatment solutions, MacTel clinical trials, and more.See details»
Neurotech Pharmaceuticals, Inc. Receives Priority Review of …
Jun 20, 2024 · Neurotech Pharmaceuticals, Inc. is a private, clinical stage biotechnology company and an innovator in sustained drug delivery for chronic retinal diseases. The core platform …See details»
Neurotech Provides Update on BLA for NT-501 as a Treatment
Nov 8, 2024 · Neurotech Pharmaceuticals, Inc. is a private, clinical stage biotechnology company and an innovator in sustained drug delivery for chronic retinal diseases. The core platform …See details»
FDA Extends Review of CNTF Ocular Implant for Macular …
Nov 20, 2024 · NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor (CNTF), a protein that …See details»
Neurotech Pharmaceuticals, Inc. Receives Priority Review of …
Platform to deliver CNTF for the treatment of chronic retinal diseases, such as MacTel. CNTF is a potent neuroprotective protein that promotes the survival an. any and an innovator in …See details»
ASCRS 2024: New Phase III study results and near-future plans for ...
Apr 5, 2024 · At the 2024 ASCRS meeting in Boston, Massachusetts, the Ophthalmology Times Europe team caught up with Rich Small, CEO of Neurotech Pharmaceuticals. Here's what he …See details»
News | Press Releases | Neurotech Pharmaceuticals, Inc
Nov 2, 2022 · Learn more and get updates on Neurotech Pharmaceuticals corporate and how we deliver MacTel treatment solutions.See details»